BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Graft-versus-Host Disease readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Graft-versus-Host Dis
 ease\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT01804686-2041@assetmemo.bio
DTSTAMP:20261121T005721Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Ibrutinib: Phase 3 readout est. (NCT01804686)
DESCRIPTION:Ibrutinib\, phase 3\, Diffuse Large B-Cell Lymphoma.\nStudy: A 
 Long-term Extension Study of PCI-32765 (Ibrutinib)\nEstimated primary comp
 letion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/ibrutinib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT01804686
URL:https://assetmemo.bio/drug/ibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06843408-3003@assetmemo.bio
DTSTAMP:20261121T005721Z
DTSTART;VALUE=DATE:20270106
DTEND;VALUE=DATE:20270107
SUMMARY:Axatilimab: Phase 1/2 readout est. (NCT06843408)
DESCRIPTION:Axatilimab\, phase 1/2\, Chronic Graft-versus-Host Disease.\nSt
 udy: A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With
  Recurrent or Refractory cGVHD\nEstimated primary completion: 6 January 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/axatilimab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06843408
URL:https://assetmemo.bio/drug/axatilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06936566-7619@assetmemo.bio
DTSTAMP:20261121T005721Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Ruxolitinib (Jakafi): Phase 2 readout est. (NCT06936566)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 2\, Graft-versus-Host Disease.\nSt
 udy: MAGIC Ruxolitinib for aGVHD\nEstimated primary completion: 1 June 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/ruxolitinib-jakafi
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT069
 36566
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07249346-7619@assetmemo.bio
DTSTAMP:20261121T005721Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Ruxolitinib (Jakafi): Phase 2 readout est. (NCT07249346)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 2\, Graft-versus-Host Disease.\nSt
 udy: Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tac
 rolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in My
 eloablative Allogeneic Peripheral Blood Stem Cell Transplantation\nEstimat
 ed primary completion: 1 June 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/ruxolitinib-jakafi#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07249346
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07340723-7619@assetmemo.bio
DTSTAMP:20261121T005721Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Ruxolitinib (Jakafi): Phase 2 readout est. (NCT07340723)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 2\, Graft-versus-Host Disease.\nSt
 udy: Novel First-line Therapies for Grade II Acute GVHD(Graft-versus-host 
 Disease )\nEstimated primary completion: 1 June 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07340723
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07366801-7619@assetmemo.bio
DTSTAMP:20261121T005721Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Ruxolitinib (Jakafi): Phase 2/3 readout est. (NCT07366801)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 2/3\, Graft-versus-Host Disease.\n
 Study: Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted He
 matopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After All
 ogeneic Hematopoietic Stem Cell Transplantation Among Children With Hemato
 logic Malignancies\nEstimated primary completion: 1 June 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07366801
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05922761-1886@assetmemo.bio
DTSTAMP:20261121T005721Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Belumosudil: Phase 2 readout est. (NCT05922761)
DESCRIPTION:Belumosudil\, phase 2\, Graft-versus-Host Disease.\nStudy: BElu
 mosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)\nEstimated
  primary completion: 30 June 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/belumosudil#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT05922761
URL:https://assetmemo.bio/drug/belumosudil#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06585774-3003@assetmemo.bio
DTSTAMP:20261121T005721Z
DTSTART;VALUE=DATE:20270928
DTEND;VALUE=DATE:20270929
SUMMARY:Axatilimab: Phase 3 readout est. (NCT06585774)
DESCRIPTION:Axatilimab\, phase 3\, Chronic Graft-versus-Host Disease.\nStud
 y: A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment
  for Chronic Graft-Versus-Host Disease\nEstimated primary completion: 28 S
 eptember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/axatil
 imab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06585774
URL:https://assetmemo.bio/drug/axatilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07356245-7619@assetmemo.bio
DTSTAMP:20261121T005721Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Ruxolitinib (Jakafi): Phase 2 readout est. (NCT07356245)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 2\, Graft-versus-Host Disease.\nSt
 udy: Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cel
 l Lymphoma\nEstimated primary completion: 31 October 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07356245
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06756061-7619@assetmemo.bio
DTSTAMP:20261121T005721Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Ruxolitinib (Jakafi): Phase 2 readout est. (NCT06756061)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 2\, Graft-versus-Host Disease.\nSt
 udy: Comparing the Therapeutic Effects of Using Ruxolitinib and Steroids C
 oncurrently to Steroids Alone as Initial Treatment In Patients Diagnosed W
 ith Chronic Graft-versus-host Disease at a Grade of Moderate or Higher Sev
 erity\nEstimated primary completion: 1 November 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06756061
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07509749-7619@assetmemo.bio
DTSTAMP:20261121T005721Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Ruxolitinib (Jakafi): Phase 2 readout est. (NCT07509749)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 2\, Graft-versus-Host Disease.\nSt
 udy: Novel Therapies for Severe Acute GVHD (Graft-versus-host Disease)\nEs
 timated primary completion: 30 December 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07509749
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06973668-7619@assetmemo.bio
DTSTAMP:20261121T005721Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Ruxolitinib (Jakafi): Phase 2 readout est. (NCT06973668)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 2\, Graft-versus-Host Disease.\nSt
 udy: A Randomized Study to Compare Post-transplant Cyclophosphamide\, Siro
 limus\, Ruxolitinib and Post-transplant Cyclophosphamide\, Sirolimus\, Myc
 ophenolate Mofetil to Prevent Graft Versus Host Disease\nEstimated primary
  completion: 31 January 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/ruxolitinib-jakafi#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06973668
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07568535-87@assetmemo.bio
DTSTAMP:20261121T005721Z
DTSTART;VALUE=DATE:20280228
DTEND;VALUE=DATE:20280229
SUMMARY:Ryoncil (remestemcel-L): Phase 3 readout est. (NCT07568535)
DESCRIPTION:Ryoncil (remestemcel-L)\, phase 3\, Graft-versus-Host Disease.\
 nStudy: A Randomized\, Double-Blind\, Placebo-Controlled\, Multicenter Pha
 se III Trial of Remestemcel-L-rknd Added to Ruxolitinib for Grade III-IV S
 teroid-Refractory Acute Graft-Versus-Host Disease\nEstimated primary compl
 etion: 28 February 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/remestemcel-l#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07568535
URL:https://assetmemo.bio/drug/remestemcel-l#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05996627-1886@assetmemo.bio
DTSTAMP:20261121T005721Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Belumosudil: Phase 2 readout est. (NCT05996627)
DESCRIPTION:Belumosudil\, phase 2\, Graft-versus-Host Disease.\nStudy: Belu
 mosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versu
 s Host Disease\nEstimated primary completion: 30 April 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/belumosudil#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT05996627
URL:https://assetmemo.bio/drug/belumosudil#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06821542-3003@assetmemo.bio
DTSTAMP:20261121T005721Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Axatilimab: Phase 3 readout est. (NCT06821542)
DESCRIPTION:Axatilimab\, phase 3\, Chronic Graft-versus-Host Disease.\nStud
 y: A Study to Evaluate Axatilimab Versus Best Available Therapy in Partici
 pants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines 
 of Systemic Therapy\nEstimated primary completion: 31 May 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/axatilimab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06821542
URL:https://assetmemo.bio/drug/axatilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06859424-7619@assetmemo.bio
DTSTAMP:20261121T005721Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Ruxolitinib (Jakafi): Phase 2 readout est. (NCT06859424)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 2\, Myelofibrosis.\nStudy: A Platf
 orm Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-V
 ersus-Host Disease Prophylaxis in Patients With Hematologic Malignancies U
 ndergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplant
 ation\nEstimated primary completion: June 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06859424
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05622318-7619@assetmemo.bio
DTSTAMP:20261121T005721Z
DTSTART;VALUE=DATE:20280708
DTEND;VALUE=DATE:20280709
SUMMARY:Ruxolitinib (Jakafi): Phase 2 readout est. (NCT05622318)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 2\, Graft-versus-Host Disease.\nSt
 udy: De-escalated Cyclophosphamide (PTCy) and Ruxolitinib for Graft-versus
 -Host Disease (GVHD) Prophylaxis\nEstimated primary completion: 8 July 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/ruxolitinib-jakafi
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT056
 22318
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07011810-3003@assetmemo.bio
DTSTAMP:20261121T005721Z
DTSTART;VALUE=DATE:20280810
DTEND;VALUE=DATE:20280811
SUMMARY:Axatilimab: Phase 2 readout est. (NCT07011810)
DESCRIPTION:Axatilimab\, phase 2\, Chronic Graft-versus-Host Disease.\nStud
 y: Axatilimab for Sclerotic Chronic Graft-versus-Host Disease\nEstimated p
 rimary completion: 10 August 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/axatilimab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07011810
URL:https://assetmemo.bio/drug/axatilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07116031-1886@assetmemo.bio
DTSTAMP:20261121T005721Z
DTSTART;VALUE=DATE:20280925
DTEND;VALUE=DATE:20280926
SUMMARY:Belumosudil: Phase 2 readout est. (NCT07116031)
DESCRIPTION:Belumosudil\, phase 2\, Graft-versus-Host Disease.\nStudy: A St
 udy of Belumosudil in Children With Chronic Graft Versus Host Disease (sch
 oolROCK)\nEstimated primary completion: 25 September 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/belumosudil#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07116031
URL:https://assetmemo.bio/drug/belumosudil#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06143891-1886@assetmemo.bio
DTSTAMP:20261121T005721Z
DTSTART;VALUE=DATE:20280929
DTEND;VALUE=DATE:20280930
SUMMARY:Belumosudil: Phase 3 readout est. (NCT06143891)
DESCRIPTION:Belumosudil\, phase 3\, Graft-versus-Host Disease.\nStudy: A St
 udy to Test an Oral Medicine\, Belumosudil\, in Combination With Corticost
 eroids in Participants at Least 12 Years of Age With Newly Diagnosed Chron
 ic Graft Versus Host Disease.\nEstimated primary completion: 29 September 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/belumosudil#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0614389
 1
URL:https://assetmemo.bio/drug/belumosudil#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06660355-7619@assetmemo.bio
DTSTAMP:20261121T005721Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Ruxolitinib (Jakafi): Phase 2 readout est. (NCT06660355)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 2\, Graft-versus-Host Disease.\nSt
 udy: Ruxolitinib vs Prednisone as First-line Therapy for cGVHD Needing Sys
 temic Therapy\nEstimated primary completion: December 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06660355
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07359859-7619@assetmemo.bio
DTSTAMP:20261121T005721Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Ruxolitinib (Jakafi): Phase 2 readout est. (NCT07359859)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 2\, Graft-versus-Host Disease.\nSt
 udy: A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in Pe
 ople With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant
 \nEstimated primary completion: January 2029. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07359859
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07124078-3003@assetmemo.bio
DTSTAMP:20261121T005721Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Axatilimab: Phase 2 readout est. (NCT07124078)
DESCRIPTION:Axatilimab\, phase 2\, Chronic Graft-versus-Host Disease.\nStud
 y: A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatr
 ic Participants With Chronic Graft-Versus-Host Disease After at Least 2 Pr
 ior Lines of Systemic Therapy (AGAVE-256)\nEstimated primary completion: 3
 1 January 2029. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/axati
 limab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07124078
URL:https://assetmemo.bio/drug/axatilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07006506-1886@assetmemo.bio
DTSTAMP:20261121T005721Z
DTSTART;VALUE=DATE:20290521
DTEND;VALUE=DATE:20290522
SUMMARY:Belumosudil: Phase 2 readout est. (NCT07006506)
DESCRIPTION:Belumosudil\, phase 2\, Graft-versus-Host Disease.\nStudy: A St
 udy of Belumosudil in People at Risk of Developing Graft-Versus-Host Disea
 se After a Stem Cell Transplant\nEstimated primary completion: 21 May 2029
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/belumosudil#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07006506
URL:https://assetmemo.bio/drug/belumosudil#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07771439-1886@assetmemo.bio
DTSTAMP:20261121T005721Z
DTSTART;VALUE=DATE:20290914
DTEND;VALUE=DATE:20290915
SUMMARY:Belumosudil: Phase 3 readout est. (NCT07771439)
DESCRIPTION:Belumosudil\, phase 3\, Graft-versus-Host Disease.\nStudy: A St
 udy to Investigate the Efficacy and Safety of Belumosudil Compared With Be
 st Available Therapy in Participants Aged 12 Years or Older With Chronic G
 raft-versus-host Disease\nEstimated primary completion: 14 September 2029.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/belumosudil#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07771439
URL:https://assetmemo.bio/drug/belumosudil#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07643025-1886@assetmemo.bio
DTSTAMP:20261121T005721Z
DTSTART;VALUE=DATE:20291130
DTEND;VALUE=DATE:20291201
SUMMARY:Belumosudil: Phase 2 readout est. (NCT07643025)
DESCRIPTION:Belumosudil\, phase 2\, Graft-versus-Host Disease.\nStudy: Belu
 mosudil With Ruxolitnib as Third Line Therapy for Chronic Graft Versus Hos
 t Disease (cGvHD)\nEstimated primary completion: November 2029. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/belumosudil#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07643025
URL:https://assetmemo.bio/drug/belumosudil#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07643025-7619@assetmemo.bio
DTSTAMP:20261121T005721Z
DTSTART;VALUE=DATE:20291130
DTEND;VALUE=DATE:20291201
SUMMARY:Ruxolitinib (Jakafi): Phase 2 readout est. (NCT07643025)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 2\, Graft-versus-Host Disease.\nSt
 udy: Belumosudil With Ruxolitnib as Third Line Therapy for Chronic Graft V
 ersus Host Disease (cGvHD)\nEstimated primary completion: November 2029. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/ruxolitinib-jakafi#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0764302
 5
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06663722-3003@assetmemo.bio
DTSTAMP:20261121T005721Z
DTSTART;VALUE=DATE:20300505
DTEND;VALUE=DATE:20300506
SUMMARY:Axatilimab: Phase 2 readout est. (NCT06663722)
DESCRIPTION:Axatilimab\, phase 2\, Chronic Graft-versus-Host Disease.\nStud
 y: Axatilimab in Combination With Extracorporeal Photopheresis (ECP) in Ch
 ronic Graft-versus-Host Disease\nEstimated primary completion: 5 May 2030.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/axatilimab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06663722
URL:https://assetmemo.bio/drug/axatilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06128070-7619@assetmemo.bio
DTSTAMP:20261121T005721Z
DTSTART;VALUE=DATE:20301122
DTEND;VALUE=DATE:20301123
SUMMARY:Ruxolitinib (Jakafi): Phase 2 readout est. (NCT06128070)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 2\, Graft-versus-Host Disease.\nSt
 udy: Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Gr
 aft Versus Host Disease in Pediatric and Young Adult Patients Undergoing A
 llogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia\, Acute
  Lymphoblastic Leukemia\, or Myelodysplastic Syndrome\nEstimated primary c
 ompletion: 22 November 2030. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/ruxolitinib-jakafi#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06128070
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06615050-7619@assetmemo.bio
DTSTAMP:20261121T005721Z
DTSTART;VALUE=DATE:20310117
DTEND;VALUE=DATE:20310118
SUMMARY:Ruxolitinib (Jakafi): Phase 3 readout est. (NCT06615050)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 3\, Graft-versus-Host Disease.\nSt
 udy: A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant
  Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Re
 duced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transpl
 antation (BMT CTN 2203)\nEstimated primary completion: 17 January 2031. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/ruxolitinib-jakafi#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06615050
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07297914-7619@assetmemo.bio
DTSTAMP:20261121T005721Z
DTSTART;VALUE=DATE:20321130
DTEND;VALUE=DATE:20321201
SUMMARY:Ruxolitinib (Jakafi): Phase 2/3 readout est. (NCT07297914)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 2/3\, Graft-versus-Host Disease.\n
 Study: Framework for Optimizing\, Refining\, and Unifying Management of HS
 CT in Pediatric ALL\nEstimated primary completion: 30 November 2032. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/ruxolitinib-jakafi#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07297914
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
